Uganda
February 2022: Dolutegravir as First- or Second-line Treatment for HIV-1 Infection in Children
Article and Study Summary: Dolutegravir as First- or Second-line Treatment for HIV-1 Infection in Children Published in: New England Journal of Medicine 2021,385(27):2531-2543. https://www.nejm.org/doi/full/10.1056/NEJMoa2108793 Authors: Turkova A, White E, Mujuru HA,...
January 2022: Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis
Article and Study Summary: Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis. Published in: New England Journal of Medicine. 2021;385(26):2441-2450 https://www.nejm.org/doi/full/10.1056/NEJMoa2105470 Authors: Cattamanchi A, Reza TF,...
July/August 2021: Comparing Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir for second-line HIV treatment: Results of the NADIA Trial in Uganda, Kenya, and Zimbabwe
Article and Study Summary: Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. Published in: N Engl J Med 2021;385(4):330-341. https://www.nejm.org/doi/full/10.1056/NEJMoa2101609 Authors: Paton NI, Musaazi J, Kityo C, et al. Summary:...


